Multiple Sclerosis

PHILADELPHIA — Remdesivir did not reduce adverse cardiovascular or kidney events in adults with underlying kidney damage hospitalized for COVID-19, a speaker here said.

A Boston-based biopharma company announced the first participants have been dosed in its phase 1 study to assess safety, tolerability and pharmacokinetics of a novel oral, small molecule therapeutic in healthy adults.

PHILADELPHIA — The protective effect of peer mentorship to reduce hospitalizations and ED visits in patients on maintenance dialysis may be population-specific, according to a study presented at ASN Kidney Week.

VANCOUVER, British Columbia — Substituting just one meat-based meal with protein from plant or dairy sources could improve metabolite signatures linked to hepatic encephalopathy in patients with cirrhosis, according to a presenter here.

Treatment with an oral suspension of active gold as an adjunct to disease-modifying therapy was linked to improved neurological function in those with stable relapsing MS, according to a poster presented at ECTRIMS 2023.

Treatment with immediate release tablets of a non-covalent Bruton’s tyrosine kinase inhibitor for relapsing forms of multiple sclerosis met pharmacokinetic and pharmacodynamic goals, data show.

Cognitive behavioral therapy, modafinil and combination therapy were each linked to reduced fatigue in patients with MS, although patients reported greater benefits with combination therapy, according to research presented at ACTRIMS 2023.